Last edition
News about "Tasman Therapeutics"
Tasman Therapeutics and Osmind Partner to Advance R-107 for Depressive Disorders
Tasman Therapeutics and Osmind are partnering to advance R-107, an investigational oral extended-release ketamine therapy, through phase 3 trials for depressive disorders.
Tasman Therapeutics | 13/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members